<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548766" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548766/" /><meta name="ncbi_pagename" content="Telbivudine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Telbivudine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Telbivudine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/10/20" /><meta name="citation_pmid" content="31644075" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548766/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Telbivudine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/10/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548766/" /><meta name="description" content="Telbivudine is a nucleoside analogue and antiviral inhibitor of hepatitis B virus (HBV) replication which is used alone and in combination with other agents in the therapy of the hepatitis B. Telbivudine does not appear to be a significant cause of drug induced liver injury, but can be associated with flares of the underlying hepatitis B either during therapy or upon withdrawal." /><meta name="og:title" content="Telbivudine" /><meta name="og:type" content="book" /><meta name="og:description" content="Telbivudine is a nucleoside analogue and antiviral inhibitor of hepatitis B virus (HBV) replication which is used alone and in combination with other agents in the therapy of the hepatitis B. Telbivudine does not appear to be a significant cause of drug induced liver injury, but can be associated with flares of the underlying hepatitis B either during therapy or upon withdrawal." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548766/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Telbivudine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548766/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89F83C0468E3C10000000001610051.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548766_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548766_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Telaprevir/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Telithromycin/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548766_"><span class="title" itemprop="name">Telbivudine</span></h1><p class="small">Last Update: <span itemprop="dateModified">October 20, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Telbivudine.OVERVIEW"><h2 id="_Telbivudine_OVERVIEW_">OVERVIEW</h2><div id="Telbivudine.Introduction"><h3>Introduction</h3><p>Telbivudine is a nucleoside analogue and antiviral inhibitor of hepatitis B virus (HBV) replication which is used alone and in combination with other agents in the therapy of the hepatitis B. Telbivudine does not appear to be a significant cause of drug induced liver injury, but can be associated with flares of the underlying hepatitis B either during therapy or upon withdrawal.</p></div><div id="Telbivudine.Background"><h3>Background</h3><p>Telbivudine (tel biv' ue deen) is the L-enantiomer of deoxythymidine (LdT) and has antiviral activity against HBV replication both in vitro and in vivo. Telbivudine is phosphorylated intracellularly to the triphosphate which inhibits the HBV polymerase and competes with deoxythymidine for incorporation into the growing viral DNA, causing inhibition of polymerase activity and DNA chain termination. Telbivudine has little or no activity against HIV replication. Telbivudine was approved in the United States in 2006 as therapy of chronic hepatitis B, either alone or in combination with other agents. It was withdrawn from the United States market in 2016 largely for economic reasons. Telbivudine was previously available as 600 mg tablets under the brand name Tyzeka. The recommended adult dose was 600 mg orally once daily. Side effects of telbivudine are uncommon. Studies of telbivudine therapy during pregnancy suggest that it is safe for pregnant women and can lower the rate of maternal-infant transmission of hepatitis B if administered in the last trimester. It was never approved for this indication in the United States.</p></div><div id="Telbivudine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Telbivudine shares many features with the other L-nucleosides (lamivudine, emtricitabine) and has been linked to transient flares of hepatitis B during and after treatment of chronic hepatitis B. Serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations above 3 times normal occurred in 5% to 10% of patients on telbivudine, which was comparable to other nucleoside analogues. Three types of flares can arise with nucleoside analogue therapy: transient and usually asymptomatic flares around the time of initiation of therapy (treatment flares), exacerbations of disease after development of antiviral resistance to telbivudine (breakthrough flares) and after stopping treatment (withdrawal flares). Cases of exacerbation of hepatitis B after development of antiviral resistance or upon telbivudine withdrawal can be severe and some cases have qualified as acute liver failure. No instances of lactic acidosis with hepatic steatosis have been reported with telbivudine therapy of hepatitis B, but isolated cases of suspected mitochondrial injury with myopathy have been reported. In trials of telbivudine therapy in pregnant women with HBsAg and HBeAg in serum and high levels of HBV DNA, therapy appeared to lessen if not eliminate maternal infant transmission, but withdrawal flares of hepatitis B occurred in some women with active disease and ALT elevations before therapy. In women with &#x0201c;immune tolerant&#x0201d; hepatitis B with high levels of HBV DNA without serum aminotransferase elevations, withdrawal flares are uncommon and levels of HBV DNA rise to previous levels on stopping therapy but without a concurrent flare of disease.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Telbivudine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The apparent absence of significant hepatotoxicity from telbivudine may be due to its lack of hepatic metabolism. In vitro, telbivudine has little activity against mitochondrial polymerase gamma, inhibition of which has been implicated in the syndrome of hepatic mitochondrial injury with lactic acidosis, steatosis and hepatic failure.</p></div><div id="Telbivudine.Outcome_and_Management"><h3>Outcome and Management</h3><p>Flares of hepatitis B during and after telbivudine therapy can range in severity from mild, transient <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations to severe acute liver injury resulting in hepatic failure and death. Flares occurring at initiation of therapy are usually mild and not associated with symptoms or jaundice. Flares associated with development of antiviral resistance and withdrawal flares can be severe. As a result, patients who develop evidence of antiviral resistance to telbivudine should be monitored carefully and switched to or have added another agent with a different pattern of resistance. Upon withdrawal of telbivudine, patients should be monitored carefully and promptly restarted on antiviral therapy if signs of severe injury arise.</p><p>Agents used in therapy of HBV infection include adefovir, emtricitabine, entecavir, lamivudine, telbivudine, tenofovir, interferon alfa and peginterferon.</p><p>Drug Class: <a href="/books/n/livertox/AntiviralAgents/">Antiviral Agents</a>, Antiretroviral Agents, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.hepatitis-b/">Hepatitis B</a> Agents</p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/NucleosideAnalogues/">Nucleoside Analogues</a>: <a href="/books/n/livertox/Abacavir/">Abacavir</a>, <a href="/books/n/livertox/Adefovir/">Adefovir</a>, <a href="/books/n/livertox/Didanosine/">Didanosine</a>, <a href="/books/n/livertox/Emtricitabine/">Emtricitabine</a>, <a href="/books/n/livertox/Entecavir/">Entecavir</a>, <a href="/books/n/livertox/Lamivudine/">Lamivudine</a>, <a href="/books/n/livertox/Stavudine/">Stavudine</a>, <a href="/books/n/livertox/Tenofovir/">Tenofovir</a>, <a href="/books/n/livertox/Zidovudine/">Zidovudine</a></p></div></div><div id="Telbivudine.PRODUCT_INFORMATION"><h2 id="_Telbivudine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Telbivudine &#x02013; Tyzeka&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiviral Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=telbivudine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Telbivudine.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Telbivudine_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Telbivudine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548766/table/Telbivudine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Telbivudine.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Telbivudine.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Telbivudine.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Telbivudine.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Telbivudine.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Telbivudine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Telbivudine</td><td headers="hd_h_Telbivudine.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135115725" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">3424-98-4</a></td><td headers="hd_h_Telbivudine.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C10-H14-N2-O5</td><td headers="hd_h_Telbivudine.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135115725" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135115725" alt="image 135115725 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Telbivudine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Telbivudine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 October 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Telbivudine.REF.n__ez.2013">N&#x000fa;&#x000f1;ez M. Hepatitis treatments. Hepatic toxicity of antiviral agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 511-2.<div><i>(Review of hepatotoxicity of antiviral agents; mentions the potential of severe flares of disease upon withdrawal of therapy in chronic hepatitis B).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.acosta.2011">Acosta EP, Flexner C. Antiviral agents (nonretroviral). In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1593-622.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.lewis.1995.417">Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. <span><span class="ref-journal">Nature Med. </span>1995;<span class="ref-vol">1</span>:417–22.</span> [<a href="/pubmed/7585087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7585087</span></a>]<div><i>(Review of mechanisms for mitochondrial injury by nucleoside analogues including inhibition of mitochondrial DNA polymerase gamma).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.lai.2005.528">Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, et al.  Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. <span><span class="ref-journal">Gastroenterology. </span>2005;<span class="ref-vol">129</span>:528–36.</span> [<a href="/pubmed/16083710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16083710</span></a>]<div><i>(One year course of telbivudine vs lamivudine vs combination of both in 104 patients with hepatitis B; ALT elevations &#x0003e;3 times ULN occurred in only 1 of 44 [2%] telbivudine-treated patients).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.chan.2007.745">Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, et al.  018 Study Group. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. <span><span class="ref-journal">Ann Intern Med. </span>2007;<span class="ref-vol">147</span>:745–54.</span> [<a href="/pubmed/17909201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17909201</span></a>]<div><i>(Trial of telbivudine vs adefovir for 52 weeks in 131 patients with chronic hepatitis B; rates of ALT elevations and flares of hepatitis were not provided).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.bridges.2008.2521">Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>2008;<span class="ref-vol">52</span>:2521–8.</span> [<a href="/pmc/articles/PMC2443876/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2443876</span></a>] [<a href="/pubmed/18474576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18474576</span></a>]<div><i>(Animal studies using high doses of telbivudine demonstrated no hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.lai.2007.2576">Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, et al. Globe Study Group.  Telbivudine versus lamivudine in patients with chronic hepatitis B. <span><span class="ref-journal">N Engl J Med. </span>2007;<span class="ref-vol">357</span>:2576–88.</span> [<a href="/pubmed/18094378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18094378</span></a>]<div><i>(Trial of telbivudine [600 mg/day] vs lamivudine [100 mg/day] for 52 weeks in 1370 patients with chronic hepatitis B; ALT &#x0003e;3 times ULN occurred in 3.7% on telbivudine vs 6.3% on lamivudine; 1 patient on lamivudine developed antiviral resistance and liver failure requiring liver transplant).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.hou.2008.447">Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, et al.  Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. <span><span class="ref-journal">Hepatology. </span>2008;<span class="ref-vol">47</span>:447–54.</span> [<a href="/pubmed/18080339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18080339</span></a>]<div><i>(Trial of telbivudine vs lamivudine for 52 weeks in 332 patients with hepatitis B; ALT elevations &#x0003e;3 times normal occurred in 9.1% of lamivudine vs 5.4% of telbivudine treated subjects, usually associated with viral breakthrough; none fatal).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.fontana.2009.s185">Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. <span><span class="ref-journal">Hepatology. </span>2009;<span class="ref-vol">49</span>(5) Suppl:S185–95.</span> [<a href="/pubmed/19399802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19399802</span></a>]<div><i>(Review of side effects of nucleoside analogues used to treat chronic hepatitis B).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.liaw.2009.486">Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, et al. GLOBE Study Group.  2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. <span><span class="ref-journal">Gastroenterology. </span>2009;<span class="ref-vol">136</span>:486–95.</span> [<a href="/pubmed/19027013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19027013</span></a>]<div><i>(2 year results from Globe trial [Lai, 2007]: ALT levels &#x0003e;3 times ULN occurred in 6.3% of telbivudine vs 11.6% of lamivudine-treated subjects; 1 patient on telbivudine with antiviral resistance developed liver failure, but survived).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.finsterer.2010.323">Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage. <span><span class="ref-journal">Virol J. </span>2010;<span class="ref-vol">7</span>:323.</span> [<a href="/pmc/articles/PMC2998482/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2998482</span></a>] [<a href="/pubmed/21083916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21083916</span></a>]<div><i>(27 year old man with chronic hepatitis B developed myalgias 3 weeks after starting telbivudine [CPK 3243 U/L], improving upon stopping).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.zou.2011.892">Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. <span><span class="ref-journal">J Viral Hepat. </span>2011;<span class="ref-vol">18</span>:892–6.</span> [<a href="/pubmed/22093034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22093034</span></a>]<div><i>(Among 200 patients with chronic hepatitis B treated with telbivudine for 3 years or more, 84% had at least one CPK elevation and 5% developed symptomatic myopathy [CPK more than 7 times ULN], but most abnormalities resolved spontaneously except in 3 patients in whom it resolved once they were switched to adefovir).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.han.2011.1215">Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, et al.  A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. <span><span class="ref-journal">J Hepatol. </span>2011;<span class="ref-vol">55</span>:1215–21.</span> [<a href="/pubmed/21703206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21703206</span></a>]<div><i>(Controlled trial of telbivudine vs no treatment during the latter part of pregnancy [starting between weeks 20 and 33] in 229 Chinese women with HBsAg, HBeAg and high levels of HBV DNA in serum; transmission of HBV to the newborn occurred in 0% of newborns of telbivudine-treated vs 8% of those of untreated mothers; after withdrawal of telbivudine after delivery in 38 mothers, none had a flare of hepatitis with ALT elevations &#x0003e;10 times ULN).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.dang.2011.73">Dang S, Gao N, Zhang X, Jia X. Rhabdomyolysis in a 48-year-old man with hepatitis B-induced cirrhosis. <span><span class="ref-journal">Am J Med Sci. </span>2011;<span class="ref-vol">342</span>:73–5.</span> [<a href="/pubmed/21642814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21642814</span></a>]<div><i>(48 year old man with chronic hepatitis B and cirrhosis developed abdominal pain and swelling and was found to have ascites and elevated CPK [3110 U/L]; despite stopping therapy, he developed progressive rhabdomyolysis and died of renal failure).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.gane.2011.676">Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. <span><span class="ref-journal">Liver Int. </span>2011;<span class="ref-vol">31</span>:676–84.</span> [<a href="/pubmed/21457439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21457439</span></a>]<div><i>(Further follow up of trial of telbivudine [Lai 2007] on safety in 399 patients treated for at least 3 years identified CPK elevations &#x0003e;7 times ULN in 55 [13%], myopathy in 22 [5%] and ALT flares &#x0003e;10 times ULN in 11 [3%]).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.chan.2012.732">Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, et al.  Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-na&#x000ef;ve patients with HBV-related decompensated cirrhosis. <span><span class="ref-journal">J Viral Hepat. </span>2012;<span class="ref-vol">19</span>:732–43.</span> [<a href="/pubmed/22967105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22967105</span></a>]<div><i>(In a controlled trial of telbivudine vs lamivudine in 228 patients with chronic hepatitis B and hepatic decompensation, the mortality rate from end stage liver disease at 2 years was 16%, but no deaths were considered drug related; one patient on telbivudine developed myopathy).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.wang.2013.158">Wang J, Wang M, Huang Y. Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: A report of two cases. <span><span class="ref-journal">Scand J Infect Dis. </span>2013;<span class="ref-vol">45</span>:158–60.</span> [<a href="/pubmed/22830672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22830672</span></a>]<div><i>(Two patients, 37 and 39 year old men, discontinued antiviral therapy [lamivudine and adefovir] on their own and developed acute on chronic hepatic failure [bilirubin 44.5 and 26.6 mg/dL, ALT 387 and 87 U/L, INR 2.47 and 2.44, HBV DNA 20,000-200,000 copies/mL], one died and one underwent emergency liver transplant despite restarting therapy with telbivudine).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.chen.2012.973">Chen EQ, Zhou TY, Bai L, Wang JR, Yan LB, Liang LB, Tang H. Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. <span><span class="ref-journal">Antivir Ther. </span>2012;<span class="ref-vol">17</span>:973–9.</span> [<a href="/pubmed/22728692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22728692</span></a>]<div><i>(Among 72 patients with chronic hepatitis B who had a suboptimal response to adefovir, lamivudine was added in 37 and telbivudine in 35 patients; no worsening of liver disease was reported).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.ahn.2012.696">Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, et al.  Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. <span><span class="ref-journal">Hepatol Int. </span>2012;<span class="ref-vol">6</span>:696–706.</span> [<a href="/pubmed/21989925" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21989925</span></a>]<div><i>(Among 42 patients with chronic hepatitis B who had lamivudine resistance, 21 were treated with adefovir alone and 21 with adefovir and telbivudine; 1 patient in each group had an ALT flare during therapy [ALT 1743 and 1362 U/L], but both evidently resolved without discontinuation).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.kim.2013.82">Kim EH, Park H, Lee KH, Ahn SH, Kim SM, Han KH. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. <span><span class="ref-journal">Clin Mol Hepatol. </span>2013;<span class="ref-vol">19</span>:82–6.</span> [<a href="/pmc/articles/PMC3622860/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3622860</span></a>] [<a href="/pubmed/23593614" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23593614</span></a>]<div><i>(28 and 25 year old brothers developed muscle weakness 5 and 12 months after starting telbivudine for hepatitis B [bilirubin 0.9 and 0.4 mg/dL, ALT 26 and 57 U/L, CPK 788 and 2992 U/L], improving upon switching to entecavir).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.wang.2013.e37">Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. <span><span class="ref-journal">J Viral Hepat. </span>2013;<span class="ref-vol">20</span>:e37–46.</span> [<a href="/pmc/articles/PMC3618368/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3618368</span></a>] [<a href="/pubmed/23490388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23490388</span></a>]<div><i>(Further follow up of controlled trials of telbivudine for chronic hepatitis B with safety data on 655 patients reported cumulative CK elevations in 104 [16%], myopathy in 4 [1%] and ALT flares in 42 [6%], 13 being early on treatment flares and 42 breakthrough flares).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.zhang.2014.468">Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. <span><span class="ref-journal">Hepatology. </span>2014;<span class="ref-vol">60</span>:468–76.</span> [<a href="/pmc/articles/PMC4282428/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4282428</span></a>] [<a href="/pubmed/25187919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25187919</span></a>]<div><i>(Among 648 HBeAg positive pregnant women with 52 weeks of follow up, treated with telbivudine, lamivudine or no therapy during the last trimester, 16% on telbivudine, 4% of lamivudine and 3% of untreated women had an on treatment flare of ALT, but all were asymptomatic and less than 5 times ULN; no mention of withdrawal flares).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.marcellin.2015.41">Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, Peng CY, et al.  Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <span><span class="ref-journal">J Hepatol. </span>2015;<span class="ref-vol">62</span>:41–7.</span> [<a href="/pubmed/25152207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25152207</span></a>]<div><i>(Among 159 HBeAg positive adults with chronic hepatitis B treated with telbivudine, peginterferon or both, neuropathy arose in 14% of those on both agents vs 2% on telbivudine alone and none of the peginterferon alone group, which led to the early discontinuation of the trial).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.wu.2015.1170">Wu Q, Huang H, Sun X, Pan M, He Y, Tan S, Zeng Y, et al.  Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2015;<span class="ref-vol">13</span>:1170–6.</span> [<a href="/pubmed/25251571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25251571</span></a>]<div><i>(Among 279 HBeAg positive women with chronic hepatitis B and high levels of HBV DNA treated with telbivudine during the last trimester, rates of transmission were 0% compared to 15% of subjects who refused antiviral therapy; no serious adverse events occurred and there was no mention of on treatment or withdrawal ALT flares).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.han.2015.754">Han GR, Jiang HX, Yue X, Ding Y, Wang CM, Wang GJ, Yang YF. Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. <span><span class="ref-journal">J Viral Hepat. </span>2015;<span class="ref-vol">22</span>:754–62.</span> [<a href="/pubmed/25641421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25641421</span></a>]<div><i>(Among 454 HBeAg positive pregnant women with chronic hepatitis B and normal ALT levels despite high levels of HBV DNA treated with telbivudine or given no therapy starting in the 2nd or 3rd trimester, rates of transmission were none vs 9% [8/86] and 46 of 236 women [20%] who discontinued therapy one month postpartum had a withdrawal flare, although in only 3 [1.3%] did levels rise about 5 times ULN and no woman required therapy as all levels eventually fell into the normal range).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.tsai.2016.95.e1">Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, et al.  Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. <span><span class="ref-journal">Clin Microbiol Infect. </span>2016;<span class="ref-vol">22</span>:95.e1–95.e7.</span> [<a href="/pubmed/26055419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26055419</span></a>]<div><i>(Among 587 Chinese patients positive chronic hepatitis B [~50% with cirrhosis] treated with tenofovir, entecavir or telbivudine for at least one year, viral resistance developed in none on tenofovir, 3.4% on entecavir and 23% of telbivudine, while renal function was stable except in those on tenofovir in whom a decrease occurred by year 5 and rates of hepatocellular carcinoma were highest among those with cirrhosis treated with telbivudine).</i></div></div></li><li><div class="bk_ref" id="Telbivudine.REF.hu.2018.429">Hu Y, Xu C, Xu B, Hu L, Liu Q, Chen J, Liu J, et al.  Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: A multicenter prospective cohort study. <span><span class="ref-journal">J Viral Hepat. </span>2018;<span class="ref-vol">25</span>:429–37.</span> [<a href="/pubmed/29193547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29193547</span></a>]<div><i>(Among 328 HBeAg positive pregnant Chinese women who were treated with telbivudine during the last trimester or elected not to receive therapy, there were similar rates of ALT elevations in the postpartum period [21% vs 20%], whereas none of the 128 infants born to treated mothers developed HBV infection compared to 2 of 156 [1.5%] infants of controls ).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548766</span><span class="label">PMID: <a href="/pubmed/31644075" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644075</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Telaprevir/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Telithromycin/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548766&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548766/?report=reader">PubReader</a></li><li><a href="/books/NBK548766/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548766" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548766" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Telbivudine. [Updated 2020 Oct 20].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548766/pdf/Bookshelf_NBK548766.pdf">PDF version of this page</a> (105K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Telbivudine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Telbivudine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Telbivudine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Telbivudine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4857254" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4857254" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4857254" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25251571" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study.</a><span class="source">[Clin Gastroenterol Hepatol. 2015]</span><div class="brieflinkpop offscreen_noflow">Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wu Q, Huang H, Sun X, Pan M, He Y, Tan S, Zeng Y, Li L, Deng G, Yan Z, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1170-6. Epub 2014 Sep 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24067902" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B.</a><span class="source">[Carcinogenesis. 2014]</span><div class="brieflinkpop offscreen_noflow">Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tian Y, Ni D, Yang W, Zhang Y, Zhao K, Song J, Mao Q, Tian Z, van Velkinburgh JC, Yang D, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Carcinogenesis. 2014 Jan; 35(1):53-61. Epub 2013 Sep 25.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17722961" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Telbivudine.</a><span class="source">[Drugs. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Telbivudine.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Keam SJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2007; 67(13):1917-29. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23390496" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.</a><span class="source">[PLoS One. 2013]</span><div class="brieflinkpop offscreen_noflow">52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessôa MG, Fassio E, Ono SK, Bessone F, Daruich J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PLoS One. 2013; 8(2):e54279. Epub 2013 Feb 4.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19225726" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Telbivudine in the treatment of chronic hepatitis B.</a><span class="source">[Adv Ther. 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Telbivudine in the treatment of chronic hepatitis B.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nash K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Adv Ther. 2009 Feb; 26(2):155-69. Epub 2009 Feb 18.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644075" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644075" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604694b79e31203af6d0e827">Telbivudine - LiverTox</a><div class="ralinkpop offscreen_noflow">Telbivudine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:18:48-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal102&amp;ncbi_phid=CE89F83C0468E3C10000000001610051&amp;ncbi_session=CE89F83C04694B71_0353SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548766%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548766&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548766/&amp;ncbi_pagename=Telbivudine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89F83C04694B71_0353SID /projects/books/PBooks@9.2 portal102 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>